Tazemetostat Clinical Trials

4 actively recruiting trials across 3 locations

No change since May 2026

Also known as: 1403254-99-8, E 7438, E-7438, E7438, EPZ 6438 +9 more

Pipeline

Phase 1: 1Phase 2: 1Phase 1/2: 2

Top Sponsors

Thomas Jefferson University1
SWOG Cancer Research Network1
Jiangsu HengRui Medicine Co., Ltd.1
Bristol-Myers Squibb1

Indications

Cancer4
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements1
Grade 3b Follicular Lymphoma1
High-grade B-cell Lymphoma1
Refractory Diffuse Large B-Cell Lymphoma1

Other1 trial

A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer

Phase 1/2

Birmingham, Alabama1 trial

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

UAB Comprehensive Cancer Center

Phase 1/2

Tucson, Arizona1 trial

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Banner University Medical Center - Tucson

Phase 2

Philadelphia, Pennsylvania1 trial

Tazemetostat and Palbociclib With CPX-351for R/R AML

Thomas Jefferson University Hospital

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.